Capital International, Inc./CA/ - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 447 filers reported holding CRISPR THERAPEUTICS AG in Q2 2024. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.

Quarter-by-quarter ownership
Capital International, Inc./CA/ ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q2 2024$5,518,634
-11.7%
102,178
+11.5%
0.07%
-13.1%
Q1 2024$6,247,614
+45.4%
91,661
+33.5%
0.08%
+25.4%
Q4 2023$4,297,740
+38.6%
68,654
+0.5%
0.07%
+13.6%
Q3 2023$3,100,727
-15.4%
68,313
+4.7%
0.06%
-11.9%
Q2 2023$3,663,135
+32.6%
65,250
+6.9%
0.07%
+21.8%
Q1 2023$2,761,518
+37.9%
61,055
+24.0%
0.06%
+27.9%
Q4 2022$2,002,013
-42.4%
49,250
-7.4%
0.04%
-44.9%
Q3 2022$3,476,000
+31.1%
53,189
+21.9%
0.08%
+110.8%
Q2 2022$2,651,000
+16.7%
43,625
+20.6%
0.04%
+48.0%
Q1 2022$2,271,000
-41.8%
36,181
-29.7%
0.02%
-30.6%
Q4 2021$3,899,000
-29.1%
51,445
+4.7%
0.04%
-32.1%
Q3 2021$5,502,000
-36.2%
49,158
-7.7%
0.05%
-31.2%
Q2 2021$8,624,000
+0.1%
53,272
-24.7%
0.08%
-3.8%
Q1 2021$8,619,000
-52.6%
70,735
-40.4%
0.08%
-52.4%
Q4 2020$18,166,000
+94.3%
118,647
+6.1%
0.17%
+63.1%
Q3 2020$9,349,000111,7800.10%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2024
NameSharesValueWeighting ↓
Versant Venture Management, LLC 508,558$82,330,00027.28%
Valiant Capital Management, L.P. 307,700$49,814,0003.74%
NEA Management Company, LLC 1,590,002$257,405,0003.35%
NIA IMPACT ADVISORS, LLC 39,891$6,458,0003.15%
Ikarian Capital, LLC 200,000$32,379,0002.62%
Soleus Capital Management, L.P. 103,114$16,693,0002.57%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 157,334$25,471,0002.47%
Capital Impact Advisors, LLC 45,440$7,356,0002.37%
ARK Investment Management 7,776,119$1,258,876,0002.34%
Sassicaia Capital Advisers LLC 13,513$2,188,0002.28%
View complete list of CRISPR THERAPEUTICS AG shareholders